143 related articles for article (PubMed ID: 32337851)
1. Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome.
Hu F; Chen SL; Dai YJ; Wang Y; Qin ZY; Li H; Shu LL; Li JY; Huang HY; Liang Y
J Cell Mol Med; 2020 Jun; 24(11):6373-6384. PubMed ID: 32337851
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
4. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
7. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
13. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome.
Wu DH; Yao DM; Yang L; Ma JC; Wen XM; Yang J; Guo H; Li XX; Qian W; Lin J; Qian J
Leuk Lymphoma; 2017 Jan; 58(1):96-103. PubMed ID: 27244225
[TBL] [Abstract][Full Text] [Related]
15. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
Mills KI; Kohlmann A; Williams PM; Wieczorek L; Liu WM; Li R; Wei W; Bowen DT; Loeffler H; Hernandez JM; Hofmann WK; Haferlach T
Blood; 2009 Jul; 114(5):1063-72. PubMed ID: 19443663
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
17. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T
J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689
[TBL] [Abstract][Full Text] [Related]
18. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
19. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.
Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW
Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942
[TBL] [Abstract][Full Text] [Related]
20. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]